FruquintinibsintilimabCAPEOXoxaliplatincapecitabinechemotherapyimmunotherapy
…cer, although there remains a need for improvement in efficacy. Fruquintinib, an oral and highly selective vascular endothelial growth facto…
7articles mentioning drugs
14drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: sintilimab ×
sintilimab
This drug is selected. Its supporting articles are shown below.
Articles mentioning sintilimab
7 articles · page 1 of 1sintilimablung cancerimmunotherapysqNSCLCchemotherapyLDRTradiotherapySBRT
…ith sintilimab and chemotherapy, while the control arm receives sintilimab with chemotherapy alone. Randomisation is stratified by PD-L1 e…
αPD-1sintilimabchronic hepatitis B (CHB)CHB
… the most common AEs, and they represented the only severe AEs. αPD-1 add-on therapy induced greater HBsAg reductions (mean decline: …
IBI305sintilimabcapecitabineCapeOXoxaliplatinbevacizumabgastric or gastro-oesophageal junction (G/GEJ) cancerchemotherapyG/GEJ
…, the patients will receive CapeOX combined with sintilimab and IBI305 at the recommended phase II dose. The primary objectives will b…
cyclophosphamidehydroxychloroquinesintilimabInnoventSecond Affiliated Hospital of Soochow UniversityThe Second Affiliated Hospital of Soochow UniversityGlioblastomaleft frontal lobe glioblastomaGB
…ment protocol comprised a preconditioning regimen consisting of cyclophosphamide (20 mg/kg/day, intravenous infusion, administered from day -5 t…
tislelizumabsintilimabInnoPCVINV002Anti-PD-1 monoclonal antibodynon-small cell lung cancerAffiliated Hospital of Guizhou Medical UniversityECOG Performance Status
… Group performance status of 0 or 1. Eligible patients received tislelizumab (200 mg, IV Q3W) or sintilimab (200 mg, IV Q3W) for a lead-in p…
SB290157sintilimabGastric cancer peritoneal metastasis (GCPM)chemotherapyGCPM
…y, disrupting the CAF-TAM axis in vivo using a C3aR antagonist (SB290157) increased CD8+ T cell infiltration and significantly enhanced …